Green Park Collaborative
A Partnership to Guide Healthcare Innovation and Effectiveness
Increasing cost pressures and new models of shared risk are driving interest in evidence on the comparative effectiveness and value of new and existing drugs, treatments, and medical devices. Payers need this evidence to determine coverage, while patients, consumers, clinicians, and others need it to make better care decisions. However, life sciences companies and clinical researchers have limited information about what the evidence payers and others need. Product developers also worry that generating additional evidence may increase the cost of clinical development and impede the pace of innovation. The result: broad uncertainty about how best to develop and test new and needed interventions.
The Green Park Collaborative - USA (GPC-USA) is a multi-stakeholder forum established to address this challenge. GPC-USA develops condition and technology-specific study design recommendations to guide the generation of evidence needed to inform both clinical and payment decisions. GPC-USA includes a diverse mix of payers,life sciences companies, patients, clinicians, researchers, regulators and other stakeholders.
- Patient-centered Outcomes in Diabetes
- Treatment Sequencing and Prioritization (Oncology)
- Next Generation Sequencing (NGS) Tests for Cancer Diagnosis and Treatment.